B cells are promising cells for the development of cell-based therapy because of their natural advantages. Creative Biolabs has developed an innovative B cell engineering platform. We provide high-efficiency B cell genome editing service for efficient transgene knock-in in the endogenous GAPDH gene via CRISPR/Cas9 mediated homologous recombination. We generate a CRISPR/CAS9 vector that contains a Cas9 expression cassette and a guide RNA (gRNA) to target GAPDH for genome engineering. A donor vector for transgene integration contains the GAPDH homologous arms flanking the gene of interest which will be integrated at the GAPDH site via homologous. The knock-in cassette is integrated into the genome of the B cells by homology-directed repair of the break, resulting in genome-edited B cells that express the gene product of interest.
Fig.1 Transgene insertion into the GAPDH Locus. (Creative Biolabs)
Genetically-engineered B cells offer unique opportunities for gene therapy through the delivery of biologics. Creative Biolabs is dedicated to developing an excellent B cell gene therapy platform for long-term, high titer expression of the protein. Our scientists have experience in B cell culture and engineering. We offer complete B cell engineering services including primary B cell isolation, engineering B cells to express a specific gene, B cell differentiation into matured plasma cells, and analysis and characterization of the modified cells.
Primary B cells isolation and culture
B cells can be designed to durably express therapeutic antibodies or proteins. Powered by our proprietary platform, our CRISPR/Cas9 knock-in system allows highly efficient gene insertion of different expression units at the GAPDH locus, thus delivering therapeutic biologics.
Our custom B cell engineering service is an integrated, end-to-end package to support the development of cell and gene-based therapies. Please feel free to contact us to find out how we help advance your research with custom B cells.
